Overview
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Background
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indication
For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Associated Conditions
- Chronic Lymphocytic Leukemia
- Hodgkins Disease (HD)
- Indolent Lymphoma
- Lymphoma
- Lymphoma, Diffuse
- MALT Lymphoma
- Mantle Cell Lymphoma (MCL)
- Nephrotic syndrome with lesion of minimal change glomerulonephritis
- Non-Hodgkin's Lymphoma (NHL)
- Waldenström's Macroglobulinemia (WM)
- Giant follicular lymphoma
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2006/12/28 | Not Applicable | UNKNOWN | Children's Cancer and Leukaemia Group | ||
2006/12/28 | Not Applicable | UNKNOWN | Children's Cancer and Leukaemia Group | ||
2006/02/02 | Phase 2 | Completed | French Innovative Leukemia Organisation | ||
2005/12/07 | Phase 3 | Completed | |||
2005/09/21 | Phase 3 | Completed | International Extranodal Lymphoma Study Group (IELSG) | ||
2005/09/09 | Phase 2 | Terminated | Cephalon | ||
2004/07/16 | Phase 3 | UNKNOWN | Scotland and Newcastle Lymphoma Group | ||
2004/03/12 | Phase 3 | Completed | |||
2004/03/12 | Phase 3 | UNKNOWN | Lymphoma Trials Office | ||
2003/01/27 | Phase 3 | UNKNOWN | Lymphoma Trials Office |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||